JPMorgan Chase & Co. Trims Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

JPMorgan Chase & Co. cut its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 54.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 30,895 shares of the company's stock after selling 37,253 shares during the period. JPMorgan Chase & Co.'s holdings in Nurix Therapeutics were worth $582,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. US Bancorp DE increased its stake in shares of Nurix Therapeutics by 144.7% in the 4th quarter. US Bancorp DE now owns 1,424 shares of the company's stock valued at $27,000 after purchasing an additional 842 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Nurix Therapeutics during the 4th quarter worth approximately $209,000. EntryPoint Capital LLC purchased a new position in shares of Nurix Therapeutics during the 4th quarter valued at approximately $266,000. China Universal Asset Management Co. Ltd. increased its holdings in Nurix Therapeutics by 21.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 15,020 shares of the company's stock worth $283,000 after acquiring an additional 2,632 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its position in Nurix Therapeutics by 18.4% during the fourth quarter. Teacher Retirement System of Texas now owns 16,263 shares of the company's stock worth $306,000 after acquiring an additional 2,532 shares during the period.

Insider Activity at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 5,825 shares of Nurix Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the transaction, the chief financial officer now owns 33,724 shares in the company, valued at approximately $488,660.76. This trade represents a 14.73 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Gwenn Hansen sold 3,377 shares of the company's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total transaction of $38,835.50. Following the sale, the insider now owns 61,516 shares in the company, valued at $707,434. The trade was a 5.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 17,838 shares of company stock worth $221,500. Company insiders own 7.40% of the company's stock.

Nurix Therapeutics Trading Up 1.0 %

Nurix Therapeutics stock traded up $0.11 during midday trading on Friday, reaching $11.27. 599,966 shares of the stock traded hands, compared to its average volume of 886,563. The firm has a market cap of $859.18 million, a PE ratio of -3.90 and a beta of 2.23. The company has a 50-day simple moving average of $12.03 and a two-hundred day simple moving average of $17.99. Nurix Therapeutics, Inc. has a 12-month low of $8.18 and a 12-month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. The firm had revenue of $18.45 million for the quarter, compared to the consensus estimate of $12.78 million. During the same period in the prior year, the firm earned ($0.76) EPS. Equities research analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on NRIX. Stephens reissued an "overweight" rating and set a $31.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. HC Wainwright reiterated a "buy" rating and set a $36.00 price objective on shares of Nurix Therapeutics in a research note on Wednesday, April 2nd. Needham & Company LLC restated a "buy" rating and issued a $27.00 target price on shares of Nurix Therapeutics in a research report on Tuesday. JPMorgan Chase & Co. dropped their price target on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. Finally, Leerink Partnrs raised shares of Nurix Therapeutics to a "hold" rating in a research note on Monday, March 17th. Three investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $30.44.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.